Cargando…

Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism

An important challenge in the field of Parkinson’s disease (PD) is to develop disease modifying therapies capable of stalling or even halting disease progression. Coupled to this challenge is the need to identify disease biomarkers, in order to identify pre-symptomatic hallmarks of disease and monit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taymans, Jean-Marc, Baekelandt, Veerle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224088/ https://www.ncbi.nlm.nih.gov/pubmed/25426138 http://dx.doi.org/10.3389/fgene.2014.00382

Ejemplares similares

The Role of α-Synuclein and LRRK2 in Tau Phosphorylation
por: Kawakami, Fumitaka, et al.
Publicado: (2015)

In Vitro Phosphorylation Does not Influence the Aggregation Kinetics of WT α-Synuclein in Contrast to Its Phosphorylation Mutants
por: Schreurs, Sarah, et al.
Publicado: (2014)

LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease?
por: O’Hara, Darren M., et al.
Publicado: (2020)

LRRK2 Kinase Activity Is Dependent on LRRK2 GTP Binding Capacity but Independent of LRRK2 GTP Binding
por: Taymans, Jean-Marc, et al.
Publicado: (2011)

Pathogenic LRRK2 requires secondary factors to induce cellular toxicity
por: Lobbestael, Evy, et al.
Publicado: (2020)

Regulation and targeting of enzymes mediating Parkinson's disease pathogenesis: focus on Parkinson's disease kinases, GTPases, and ATPases
por: Taymans, Jean-Marc, et al.
Publicado: (2014)

In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2
por: Vancraenenbroeck, Renée, et al.
Publicado: (2014)

Multiple-Hit Hypothesis in Parkinson’s Disease: LRRK2 and Inflammation
por: Cabezudo, Diego, et al.
Publicado: (2020)

PAK6 Phosphorylates 14-3-3γ to Regulate Steady State Phosphorylation of LRRK2
por: Civiero, Laura, et al.
Publicado: (2017)

Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
por: Lobbestael, E., et al.
Publicado: (2016)

LRRK2 Phosphorylation, More Than an Epiphenomenon
por: Marchand, Antoine, et al.
Publicado: (2020)

Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes
por: Sejwal, Kushal, et al.
Publicado: (2017)

Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation
por: Madero-Pérez, Jesús, et al.
Publicado: (2018)

Phosphorylation of Tau and α-Synuclein Induced Neurodegeneration in MPTP Mouse Model of Parkinson’s Disease
por: Hu, Shanshan, et al.
Publicado: (2020)

The Parkinson's Disease Associated LRRK2 Exhibits Weaker In Vitro Phosphorylation of 4E-BP Compared to Autophosphorylation
por: Kumar, Azad, et al.
Publicado: (2010)

LRRK2 interactions with α-synuclein in Parkinson’s disease brains and in cell models
por: Guerreiro, Patrícia Silva, et al.
Publicado: (2012)

LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation
por: Bae, Eun-Jin, et al.
Publicado: (2018)

LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?
por: Taymans, Jean-Marc, et al.
Publicado: (2016)

Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
por: Henderson, Michael X., et al.
Publicado: (2019)

LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons
por: Henderson, Michael X., et al.
Publicado: (2018)

Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain
por: Xu, Enquan, et al.
Publicado: (2022)

Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues
por: Iannotta, Lucia, et al.
Publicado: (2020)

α‐synuclein RT‐QuIC in cerebrospinal fluid of LRRK2‐linked Parkinson's disease
por: Garrido, Alicia, et al.
Publicado: (2019)

Overexpression of Parkinson’s Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology
por: Xiong, Yulan, et al.
Publicado: (2017)

LRRK2 phosphorylates novel tau epitopes and promotes tauopathy
por: Bailey, Rachel M., et al.
Publicado: (2013)

Plasma α‐synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson’s disease
por: Ren, Jingru, et al.
Publicado: (2022)

α-Synuclein serine129 phosphorylation – the physiology of pathology
por: Ramalingam, Nagendran, et al.
Publicado: (2023)

Parkinson-causing mutations in LRRK2 impair the physiological tetramerization of endogenous α-synuclein in human neurons
por: Fonseca-Ornelas, Luis, et al.
Publicado: (2022)

Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration
por: Van Rompuy, Anne-Sophie, et al.
Publicado: (2015)

LRRK2 Phosphorylates Tubulin-Associated Tau but Not the Free Molecule: LRRK2-Mediated Regulation of the Tau-Tubulin Association and Neurite Outgrowth
por: Kawakami, Fumitaka, et al.
Publicado: (2012)

Alpha-Synuclein and LRRK2 in Synaptic Autophagy: Linking Early Dysfunction to Late-Stage Pathology in Parkinson’s Disease
por: Lamonaca, Giulia, et al.
Publicado: (2020)

Chronic nigral neuromodulation aggravates behavioral deficits and synaptic changes in an α-synuclein based rat model for Parkinson’s disease
por: Torre-Muruzabal, Teresa, et al.
Publicado: (2019)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2017)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2021)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2021)

Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases()
por: Mamais, Adamantios, et al.
Publicado: (2013)

Pathological Functions of LRRK2 in Parkinson’s Disease
por: Jeong, Ga Ram, et al.
Publicado: (2020)

Oligomerization of Lrrk controls actin severing and α-synuclein neurotoxicity in vivo
por: Sarkar, Souvarish, et al.
Publicado: (2021)

Initiation and progression of α-synuclein pathology in Parkinson’s disease
por: Tofaris, George K.
Publicado: (2022)

Granulovacuolar degeneration bodies are independently induced by tau and α-synuclein pathology
por: Jorge-Oliva, Marta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7pp7uienl8p3g8lqr3csibo287